2023 layoffs now match 2022 total

This Week

Aug 25, 2023

Biogen kicks off 1,000 layoffs as part of CEO Chris Viehbacher's 'complete redesign'


J&J ends R&D at Janssen's infectious disease and vaccine unit


Novartis to lay off another 100-plus employees at US HQ as global restructuring rolls on


Fierce Biotech analysis: 2023 biopharma layoffs now match 2022's total


Roche posts interim TIGIT overall survival data after 'inadvertent disclosure,' sending stocks up


Merck's Keytruda will top pharma's sales rankings in 2028, with Roche taking the company category crown: Evaluate

 

Featured

Biogen kicks off 1,000 layoffs as part of CEO Chris Viehbacher's 'complete redesign'

It was only last spring that Biogen started layoffs that eventually shrank the company’s headcount by nearly 900 people last year. Now, a fresh round of job cuts targeting 1,000 positions has kicked off at the struggling drugmaker. At the same time, Biogen is spending $7.3 billion to buy rare disease specialist Reata Pharmaceuticals.
11-14
Sep
Philadelphia, PA
 

Top Stories

J&J ends R&D at Janssen's infectious disease and vaccine unit

More than six months after Johnson & Johnson merged its infectious disease and vaccine units, the healthcare giant is cutting research and development for the unit altogether, according to sources familiar with the decision. 

Novartis to lay off another 100-plus employees at US HQ as global restructuring rolls on

Novartis is cutting another 103 jobs at its U.S. headquarters in New Jersey, where the pharma giant just recently executed a 285-person round of layoffs.

Fierce Biotech analysis: 2023 biopharma layoffs now match 2022's total

Layoffs in the biotech industry for 2023 have matched the total number of companies that cut staff in all of 2022, with 119 biopharmas reporting workforce reductions so far this year, according to an analysis of Fierce Biotech data. 

Roche posts interim TIGIT overall survival data after 'inadvertent disclosure,' sending stocks up

An “inadvertent disclosure” has given the world a look at Roche’s eagerly anticipated TIGIT data. Having kept its cards close to its chest throughout the phase 3 lung cancer study, the Swiss drugmaker published interim overall survival results Wednesday after they were mistakenly made public.

Merck's Keytruda will top pharma's sales rankings in 2028, with Roche taking the company category crown: Evaluate

Merck cancer superstar Keytruda is projected to be the world’s top selling drug by a huge margin in 2028, according to a report by Evaluate. On its list of top 10 drugs by sales in 2028, Keytruda is expected to top the $30 billion mark, with no other therapy predicted to reach $20 billion in sales.

AI drug designer Genesis Therapeutics forges $200M round with eye on clinical testing

First spun out of Stanford University in late 2019, the company's deep learning platform helps design small-molecule drug compounds and predicts how they interact with the body.

Novo Nordisk tapped Thermo Fisher to help make obesity drug Wegovy amid Catalent woes: Reuters

Novo Nordisk is struggling to meet strong demand for Wegovy, and the company has reportedly tapped another contract manufacturer to churn out the popular weight-loss drug.

Bayer survey reveals deep-seated fears of Americans around cancer as pharma looks to plug education gap

Bayer has tapped the Harris Poll for a new survey on how Americans feel about finding out if they have cancer, and the results have revealed a worrying trend.

Pink Floyd song reconstruction from brain waves adds another brick to the future of voice and hearing technology

Researchers have, for the first time, reconstructed a tune from a person’s brain activity as they listened to a song, a feat that marks a major milestone in scientists’ ability to decode and understand how the brain perceives music. It could eventually make assistive voice technologies and speech prosthetics better at replicating human speech by improving their prosody.
 
Fierce podcasts

Don’t miss an episode

'The Top Line': Trends at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage

This week on "The Top Line," we discuss the trends seen at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage
 

Resources

Whitepaper

Challenges of Cell Line Development: Stable Transfection

Unravel the intricacies of Cell Line Development in biotherapeutics production with our latest eBook chapter.
Whitepaper

Plan for success with your process liquid and buffer preparation

Learn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity.
Video

Decipher the Blueprint for Your Clinical Development Transformation

Learn how to turn patient-focused innovations into life-changing treatments.
Whitepaper

Key Drivers of Sales Force Strategy in Oncology

In oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today.
Research

Reduce chemical lead times with just-in-time delivery

Learn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery.
 
 

Upcoming Fierce Events

11-14
Sep
Philadelphia, PA
13
Sep
Philadelphia, PA
19-21
Sep
Virtual Event
26-28
Sep
Philadelphia, PA
5-6
Oct
San Diego, CA

View all events